GlassScriptPhysician profile
Daniel Lopez Infante
NPI 1932762309
$2,021.20
in general payments reported to CMS, 2019-2025
16 companies · $571 in 2025
The $571 reported for 2025 was more than what 86% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $65.42 · 2021: $101 · 2022: $178 · 2023: $276 · 2024: $829 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,677.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $603.63 | 2023-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $455.47 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.08 | 2021-2024 | Jardiance, Synjardy |
| Lilly USA, LLC | $171.76 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $120.80 | 2023-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $111.74 | 2023-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $72.43 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $65.42 | 2020 | |
| Boston Scientific Corporation | $49.81 | 2024 | |
| Mylan Specialty L.P. | $42.43 | 2023-2024 | Yupelri |
| Abbvie INC. | $28.65 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $22.60 | 2024 | Eliquis |
| Abbott Laboratories | $22.28 | 2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $22.08 | 2025 | Gvoke Hypopen |
| Corcept Therapeutics | $20.79 | 2025 | Korlym |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $16.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lopez Infante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.